Any serious adverse event of treatment count of events · people with traumatic head injuries
Antiepileptic drugs showed no clear difference in any serious adverse event of treatment count of events compared with placebo or standard care (low certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
It is very uncertain whether betahistine changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with vestibular migraine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with primary central sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review